SCHEMBL17818932

SCHEMBL17818932

CC(C)(C)OC(=O)N1CCC1(C)CO

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CTSK P43235 1/20 0.38
NR1H2 P55055 1/20 0.37
CYP4F2 P78329 1/20 0.36
CYP4A11 Q02928 1/20 0.36
GRIN2B Q13224 1/20 0.34
GRIN2C Q14957 1/20 0.34
HPGD P15428 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
ABCB1 P08183 1/20 0.33
EPHX2 P34913 1/20 0.33
KDM1A O60341 1/20 0.32
DDB1 Q16531 1/20 0.32
CRBN Q96SW2 1/20 0.32
BUB1 O43683 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15425362 0.90 GRIN2B (0.41) USP2SMN1; SMN2CTSKNR1H2CYP4F2
SCHEMBL705582 0.90 GRIN2B (0.41) USP2SMN1; SMN2CTSKNR1H2CYP4F2
SCHEMBL8950858 0.90 GRIN2B (0.41) USP2SMN1; SMN2CTSKNR1H2CYP4F2
SCHEMBL21530335 0.89 CTSK (0.39) USP2SMN1; SMN2CTSKNR1H2CYP4F2
SCHEMBL21530334 0.89 CTSK (0.39) USP2SMN1; SMN2CTSKNR1H2CYP4F2
SCHEMBL20399337 0.89 CTSK (0.39) USP2SMN1; SMN2CTSKNR1H2CYP4F2
SCHEMBL3639172 0.81 USP2 (0.41) USP2SMN1; SMN2NR1H2CYP4F2CYP4A11
SCHEMBL28273267 0.81 USP2 (0.40) USP2SMN1; SMN2CTSKNR1H2CYP4F2
SCHEMBL24999596 0.80 USP2 (0.47) USP2SMN1; SMN2CTSKNR1H2CYP4F2
SCHEMBL22169112 0.80 USP2 (0.34) USP2SMN1; SMN2CTSKNR1H2CYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111582-A1 AZA-TETRACYCLIC OXAZEPINE INHIBITORS OF KRAS-G12D GENENTECH, INC. (US) 2025-05-30 WO disclosed
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES Clear Creek Bio, Inc. (US) 2025-01-23 US disclosed
US-20240307362-A1 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS BAYER AKTIENGESELLSCHAFT (DE) 2024-09-19 US disclosed
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES CILAG AG (CH) 2024-05-30 US disclosed
EP-4284802-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Janssen Biotech, Inc. (US) 2023-12-06 EP disclosed
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ANTARES THERAPEUTICS, INC. 2023-11-16 US disclosed
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ANTARES THERAPEUTICS, INC. 2023-11-16 US disclosed
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ANTARES THERAPEUTICS, INC. 2023-11-16 US disclosed
CN-116997549-A Pyrrolo [3,2-C ] pyridin-4-one derivatives for the treatment of cancer 蝎子疗法股份有限公司 2023-11-03 CN disclosed
EP-4217070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Scorpion Therapeutics, Inc. (US) 2023-08-02 EP disclosed
EP-3959212-A1 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS Bayer Aktiengesellschaft (DE) 2022-03-02 EP disclosed
CN-107207476-B Indole and azaindole derivatives and their use in neurodegenerative diseases 默克专利有限公司 2021-03-19 CN disclosed
WO-2020216773-A1 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS BAYER AKTIENGESELLSCHAFT (DE) 2020-10-29 WO disclosed
US-10676433-B2 Indole derivatives and their use in neurodegenerative diseases MERCK PATENT GMBH (DE) 2020-06-09 US disclosed
US-10323000-B2 Indole derivatives and their use in neurodegenerative diseases MERCK PATENT GMBH (DE) 2019-06-18 US disclosed
US-20190161447-A1 NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES MERCK PATENT GMBH (DE) 2019-05-30 US disclosed
EP-3233841-A1 INDOLE AND AZAINDOLES DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES Merck Patent GmbH (DE) 2017-10-25 EP disclosed
CN-107207476-A Indoles and 7-azaindole derivatives and its for the purposes in neurodegenerative disorders 默克专利有限公司 2017-09-26 CN disclosed
WO-2016100281-A1 INDOLE AND AZAINDOLES DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES MERCK PATENT GMBH (DE) 2016-06-23 WO disclosed
US-20160168090-A1 NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES MERCK PATENT GMBH (DE) 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168090-A1 NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES P2RX3, P2RX7, P2RX2 USP2 3544/4885SMN1; SMN2 1322/4885CTSK 2774/4885
US-10323000-B2 Indole derivatives and their use in neurodegenerative diseases P2RX3, ADORA2A, P2RX7 USP2 3683/4885SMN1; SMN2 1258/4885CTSK 2810/4885
US-20190161447-A1 NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES P2RX3, P2RX7, P2RX2 USP2 3544/4885SMN1; SMN2 1322/4885CTSK 2774/4885
US-20240307362-A1 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS CYP4B1, CYP2C19, CYP3A4 USP2 4314/4885SMN1; SMN2 483/4885CTSK 1429/4885
US-10676433-B2 Indole derivatives and their use in neurodegenerative diseases P2RX3, ADORA2A, P2RX7 USP2 3683/4885SMN1; SMN2 1258/4885CTSK 2810/4885
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ERBB2, EGFR, ERBB3 USP2 3142/4885SMN1; SMN2 3294/4885CTSK 4044/4885
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES SIK2, SIK1, SGK2 USP2 2482/4885SMN1; SMN2 3406/4885CTSK 1178/4885
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES ACE, PREP, PEPD USP2 320/4885SMN1; SMN2 4601/4885CTSK 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.